OptimizeRx (NASDAQ:OPRX – Get Free Report) and Triple P (OTCMKTS:TPPPF – Get Free Report) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Risk & Volatility
OptimizeRx has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Triple P has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.
Valuation & Earnings
This table compares OptimizeRx and Triple P”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OptimizeRx | $109.43 million | 0.88 | $5.13 million | $0.35 | 14.60 |
| Triple P | N/A | N/A | N/A | N/A | N/A |
OptimizeRx has higher revenue and earnings than Triple P.
Analyst Ratings
This is a summary of recent ratings and target prices for OptimizeRx and Triple P, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OptimizeRx | 1 | 2 | 6 | 0 | 2.56 |
| Triple P | 0 | 0 | 0 | 0 | 0.00 |
OptimizeRx presently has a consensus target price of $13.43, indicating a potential upside of 162.79%. Given OptimizeRx’s stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Triple P.
Institutional & Insider Ownership
76.5% of OptimizeRx shares are held by institutional investors. 5.6% of OptimizeRx shares are held by insiders. Comparatively, 39.0% of Triple P shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares OptimizeRx and Triple P’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OptimizeRx | 6.37% | 10.86% | 7.93% |
| Triple P | N/A | N/A | N/A |
Summary
OptimizeRx beats Triple P on 9 of the 10 factors compared between the two stocks.
About OptimizeRx
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
About Triple P
Triple P. N.V. provides information and communication technology (ICT) infrastructure solutions. Its services include ICT security, cloud, managed services, managed IP telephony, professional services, business continuity, unified communications, and cloud migration. The company serves care, education, government, and commercial services sectors. Triple P. N.V. was founded in 1989 and is headquartered in Nieuwegein, the Netherlands.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
